Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Shares Outstanding: 2015-2025

Historic Shares Outstanding for Editas Medicine (EDIT) over the last 8 years, with Sep 2025 value amounting to $93.3 million.

  • Editas Medicine's Shares Outstanding rose 12.99% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 12.99%. This contributed to the annual value of $82.7 million for FY2024, which is 1.18% up from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Shares Outstanding is $93.3 million, which was up 6.72% from $87.4 million recorded in Q2 2025.
  • Over the past 5 years, Editas Medicine's Shares Outstanding peaked at $93.3 million during Q3 2025, and registered a low of $67.5 million during Q1 2021.
  • Over the past 3 years, Editas Medicine's median Shares Outstanding value was $82.4 million (recorded in 2024), while the average stood at $82.6 million.
  • Data for Editas Medicine's Shares Outstanding shows a peak YoY increased of 23.12% (in 2021) over the last 5 years.
  • Over the past 5 years, Editas Medicine's Shares Outstanding (Quarterly) stood at $68.4 million in 2021, then grew by 0.60% to $68.8 million in 2022, then increased by 18.77% to $81.8 million in 2023, then increased by 1.18% to $82.7 million in 2024, then increased by 12.99% to $93.3 million in 2025.
  • Its Shares Outstanding was $93.3 million in Q3 2025, compared to $87.4 million in Q2 2025 and $83.7 million in Q1 2025.